Cite
HARVARD Citation
Biemans, V. et al. (2020). Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti‐TNF treatment. Alimentary pharmacology & therapeutics. 52 (1), pp. 123-134. [Online].